Cytokine-induced memory-like NK cells(Wugen)(Cytokine-induced memory-like NK cells(Wugen)) - 在研适应症：骨髓增生异常综合征，难治性急性髓细胞白血病_专利_临床

概要

基本信息

药物类型

细胞因子诱导的杀伤细胞疗法

别名-

靶点-

作用机制

细胞替代物

治疗领域

肿瘤血液及淋巴系统疾病

在研适应症

骨髓增生异常综合征难治性急性髓细胞白血病

非在研适应症-

原研机构

Wugen, Inc.

在研机构

Washington University School of Medicine

Wugen, Inc.

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 Cytokine-induced memory-like NK cells(Wugen) 相关的临床试验

NCT04354025 / Withdrawn临床2期IIT

A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed AML

This phase 2 clinical trial investigates the effectiveness of cytokine-induced memory-like natural killer (CIML NK) cells in combination with FLAG chemotherapy as a treatment for refractory or relapsed AML. Previous studies in adults with AML sowed successful induction of remission and a previous phase 1 study demonstrated that CIML NK cells can be used safely in pediatric patients. This phase 2 study uses FLAG chemotherapy to lower leukemic burden and suppress the recipient's immune system to provide an optimal environment for CIML NK cell expansion and anti-leukemic activity.

开始日期2023-06-30

申办/合作机构

Washington University School of Medicine

NCT04893915 / Withdrawn临床2期IIT

A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS

Patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) will receive lymphodepleting chemotherapy (Flu/Cy) and two infusions of cytokine-induced memory-like NK cells at the previously defined maximum tolerated dose (MTD), fourteen days apart. Low dose rhIL-2 will be administered to patients for in vivo expansion following cell infusion. Patients will be assessed for anti-leukemic efficacy and safety. Re-infusion of patients who relapsed after clinical response will be considered.

开始日期2022-06-30

申办/合作机构

Washington University School of Medicine

[+1]

100 项与 Cytokine-induced memory-like NK cells(Wugen) 相关的临床结果

登录后查看更多信息

100 项与 Cytokine-induced memory-like NK cells(Wugen) 相关的转化医学

登录后查看更多信息

100 项与 Cytokine-induced memory-like NK cells(Wugen) 相关的专利（医药）

登录后查看更多信息

100 项与 Cytokine-induced memory-like NK cells(Wugen) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
骨髓增生异常综合征	临床2期	美国	Washington University School of Medicine	2022-06-30
骨髓增生异常综合征	临床2期	美国	Wugen, Inc.	2022-06-30
难治性急性髓细胞白血病	临床2期	美国	Washington University School of Medicine	2022-06-30
难治性急性髓细胞白血病	临床2期	美国	Wugen, Inc.	2022-06-30